HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY
Weekly Update
How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Petruolo, O., Sevilimedu, V., Montagna, G. et al.
https://doi.org/10.1245/s10434-020-08593-5
Citation:
Petruolo, O., Sevilimedu, V., Montagna, G. et al. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? Ann Surg Oncol 28, 287–294 (2021).
Synopsis: The authors evaluate breast-conserving surgery (BCS) conversion rates with neoadjuvant chemotherapy (NAC) in patients with tumors too large for conservation. Borderline-BCS candidacy, HER2+/triple negative receptor status, tumor size, cN+ status, and mammographic calcifications are factors to consider when selecting patients for downstaging with NAC.
Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer
Miller, A.M., Lemke-Miltner, C.D., Blackwell, S. et al.
https://doi.org/10.1245/s10434-020-08591-7
Citation: Miller, A.M., Lemke-Miltner, C.D., Blackwell, S. et al. Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer. Ann Surg Oncol 28, 1187–1197 (2021).
Synopsis: Peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer is a deadly condition with limited treatment options. CMP-001 is a virus-like particle containing a TLR9 agonist that is shown here to be a new potential effective treatment when given intraperitoneally.
Listen to the ASO's new podcast, Speaking of SurgOnc®
Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.
Listen to the podcast here.
ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.
Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.
